Job Cuts Seen At Dr Reddy’s Amid Cost Recalibration
Dr Reddy’s Laboratories has set in motion significant cost control initiatives as part of broader efforts to emerge leaner and more nimble. Headcount rationalization in R&D is rumored to be already underway, while more operational areas could potentially see significant manpower reductions.
You may also be interested in...
India Pharma Q1 Preview: Home Gains But Subdued US Growth
Leading Indian firms are expected to report revenue growth, propped by a strained domestic business in the first quarter of the last fiscal year. But it is management commentary around pricing developments in the US, a key revenue contributor for most frontline firms, and plans around specialty product introductions that are expected to be keenly tracked by investors.
Novo Nordisk Seen Readying Steps To Offset US Pressures, Including Job Cuts
Novo Nordisk is rumored to be considering laying off up to 3,000 staff and dropping its long-term financial targets due to challenging US market conditions which the group flagged in its first-quarter update in May.
Schultz Swings The Cleaver At Teva, Cutting 25% Of The Workforce
Troubled Teva has been preparing employees for layoffs, but the final plan will reshape the generic drug giant entirely with 14,000 jobs being cut in a scramble to stabilize the company. Every business area and geography will be affected.